Business Context and Reporting Period
Zura Bio Limited, a Cayman Islands-based emerging growth company, filed this Form 8-K on March 28, 2023, reporting events occurring on March 23, 2023. The filing primarily addresses a side letter agreement related to a Forward Purchase Agreement (FPA) with Athanor Master Fund, LP and Athanor International Master Fund, LP (collectively, "FPA Investors").
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses on capital structure adjustments and share issuance details:
- Share Issuance: FPA Investors purchased an aggregate of 3,000,000 Class A Ordinary Shares at $10 per share ($30,000,000 total).
- Redemption Adjustment: An additional 1,301,633 Class A Ordinary Shares were purchased at $10 per share ($13,016,330 total) due to public share redemptions exceeding 90% at the time of the business combination.
- Consideration Shares: An additional 2,500,000 Class A Ordinary Shares were issued to FPA Investors for entering into the latest amendment, with no additional monetary consideration.
Material Changes
The material change reported is the execution of a "Forward Purchase Agreement Side Letter" dated March 23, 2023. This agreement imposes specific restrictions on the transfer of the 2,500,000 additional Class A Ordinary Shares issued to the FPA Investors. These shares are restricted from transfer until March 20, 2024.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release issued on March 27, 2023, which is incorporated by reference. The filing itself does not provide specific forward-looking guidance, management commentary on operational outlook, or detailed risk factors beyond the transfer restrictions noted in the side letter. The information in Item 7.01 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Side Letter (Exhibit 10.1) to understand all covenants and restrictions on the 2,500,000 shares.
- Review the March 27, 2023 Press Release (Exhibit 99.1) for operational updates or strategic context not detailed in the 8-K.
- Confirm the total outstanding share count post-issuance to assess dilution impact.
- Check subsequent filings for any updates on the FPA Investors' status or the lifting of transfer restrictions.